Abstract: A method of operation of a provider controlling platform system includes: determining a provider criterion for selecting a service provider; determining a device capability for selecting a device service for a peripheral device; generating a selection threshold based on the provider criterion, the device capability, or a combination thereof for executing the device service; and generating a service command based on the selection threshold meeting or exceeding a service request for commanding the peripheral device to execute the device service.

Abstract: The invention relates to a method for obtaining membrane vesicles enriched in membrane transport proteins of plant origin, for cosmetic or therapeutic use, which can contain other substances, such as natural bioactive compounds. Preferably, said vesicles are obtained from plants of the Brassicaceae (cruciferae) family. In addition, the invention relates to a method for increasing these proteins of plant origin.

Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.

Abstract: Pharmaceutical compositions containing a fluoroquinolone antibiotic drug are disclosed. The compositions exhibit improved homogeneity, improved bioavailability, lower turbidity or a combination thereof. The composition can be use as otic or nasal compositions, but are particularly useful as ophthalmic compositions.

Abstract: The present invention is related with the application of an adsorbent material of microporous carbon (MCA), prepared from the direct pyrolysis of copolymers generically known as Saran, in adsorption processes to reduce the benzene content in naphtha boiling range hydrocarbon streams, between 27 and 191° C., in which is preferable to perform a first separation by distillation of the C6's fraction, and a further separation of Benzene by adsorption through an adsorbent material bed, obtaining the fraction of C6's free of Benzene and an adsorbent with Benzene, which is further regenerated by pressure or temperature swing desorption or by displacement using a desorbent such as an inert gas at high temperature or by passing a desorbent which after the process, the desorbent and Benzene are separated by distillation. The fraction of C6's free of Benzene is reintegrated to the hydrocarbon stream and providing a gasoline with a Benzene content less than 1 volume %.

Abstract: A method of operation of a provider controlling platform system includes: determining a provider criterion for selecting a service provider; determining a device capability for selecting a device service for a peripheral device; generating a selection threshold based on the provider criterion, the device capability, or a combination thereof for executing the device service; and generating a service command based on the selection threshold meeting or exceeding a service request for commanding the peripheral device to execute the device service.

Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.

Abstract: The present invention is related with the application of an adsorbent material of microporous carbon (MCA), prepared from the direct pyrolysis of copolymers generically known as Saran, in adsorption processes to reduce the benzene content in naphtha boiling range hydrocarbon streams, between 27 and 191° C., in which is preferable to perform a first separation by distillation of the C6's fraction, and a further separation of Benzene by adsorption through an adsorbent material bed, obtaining the fraction of C6's free of Benzene and an adsorbent with Benzene, which is further regenerated by pressure or temperature swing desorption or by displacement using a desorbent such as an inert gas at high temperature or by passing a desorbent which after the process, the desorbent and Benzene are separated by distillation. The fraction of C6's free of Benzene is reintegrated to the hydrocarbon stream and providing a gasoline with a Benzene content less than 1 volume %.

Abstract: Pharmaceutical compositions containing a fluoroquinolone antibiotic drug are disclosed. The compositions exhibit improved homogeneity, improved bioavailability, lower turbidity or a combination thereof. The composition can be use as otic or nasal compositions, but are particularly useful as ophthalmic compositions.

Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.

Abstract: The invention relates to an apparatus for monitoring the water vapor in a freeze-drying process of, for example, pharmaceutical products.

Abstract: A pharmaceutical composition for the treatment and/or prevention of septic shock has VPAC1, VPAC2 or PAC1 receptor agonist combined with a pharmaceutically acceptable carrier. A method for treating or preventing septic shock is provided as well in which a therapeutically effective amount of the pharmaceutical composition is administered to a patient.

Abstract: Method for the treatment of endotoxic shock in mammals. The use of vasoactive intestinal peptide (VIP) and peptide activating hypofissiary adenylate cyclase (PACAP) is described in the treatment of endotoxic shock in mammals. These substances inhibit the production of tumor necrosis factor (TNF) and interleukin 6 (IL-6).